Takeda Pharmaceutical Company Limited (TKPHF)
| Previous close | 27.86 |
| Open | 27.86 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 27.86 - 27.86 |
| 52-week range | 25.57 - 34.68 |
| Volume | |
| Avg. volume | 64,645 |
| Market cap | 43.255B |
| Beta (5Y monthly) | 0.90 |
| PE ratio (TTM) | 26.04 |
| EPS (TTM) | 1.07 |
| Earnings date | N/A |
| Forward dividend & yield | 1.38 (4.96%) |
| Ex-dividend date | 29 Sept 2022 |
| 1y target est | N/A |
- Business Wire
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
OSAKA, Japan & CAMBRIDGE, Mass., June 30, 2022--Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of TAKHZYRO® (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients.1 There are currently no lo
- Bloomberg
Takeda Is ‘Now In a Good Phase’ for Growth, CEO Weber Says
(Bloomberg) -- Takeda Pharmaceutical Co.’s shares might be trading at about half of their level before the $62 billion acquisition of Shire in 2018, but the drug pipeline and cash management are helping to change the market’s perception of the company’s long-term value, Chief Executive Officer Christophe Weber said.Most Read from BloombergTrump’s Final Scene Didn’t Go According to ScriptDemocrats Weigh Paring Biden Tax Hike to Win Over ManchinVenice Plans to Start Weeding Out Cheap TouristsFauci
- Business Wire
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
OSAKA, Japan & PASADENA, Calif., June 27, 2022--Results from Phase 2 Study of fazirsiran in patients with alpha-1 antitrypsin deficiency published in New England Journal of Medicine.
